Treatment with anti-JAM-C antibody delays onset of K/BxN serum transfer-induced arthritis

<p><b>Copyright information:</b></p><p>Taken from "Expression and function of junctional adhesion molecule-C in human and experimental arthritis"</p><p>http://arthritis-research.com/content/9/4/R65</p><p>Arthritis Research & Therapy 2007;9(4):R65-R65.</p><p>Published online 5 Jul 2007</p><p>PMCID:PMC2206366.</p><p></p> Incidence of K/BxN serum transfer-induced arthritis is shown for anti-JAM-C antibody-treated (= 10, black symbols) and isotype-matched control antibody-treated (= 10, open symbols) mice. Results are expressed as the percentage of arthritic mice per group. Incidence of arthritis was significantly lower in anti-JAM-C antibody-treated mice as compared to isotype-matched antibody-treated controls on day 3. *< 0.05 versus control mice, as assessed by chi-square test. Severity of K/BxN serum transfer-induced arthritis. Arthritis was evaluated by clinical assessment of arthritis severity scores for anti-JAM-C antibody-treated (= 10, black symbols) and isotype-matched control antibody-treated (= 10, open symbols) mice. Results shown represent the mean ± standard error of the mean (SEM) for each group of mice. There were no significant differences between the groups. Histological assessment of arthritis. Representative sections are shown for anti-JAM-C antibody-treated (upper panels) and isotype-matched control antibody-treated (lower panels) mice 13 days after serum transfer. Original magnifications × 40 (left panel) (scale bar = 125 μm) and × 100 (right panel) (scale bar = 50 μm). Histological scores for synovial thickness, exudates, and edema 13 days after serum transfer. Results shown represent the mean ± SEM for anti-JAM-C antibody-treated (= 10, black columns) and isotype-matched control antibody-treated (= 10, open columns) mice. No significant differences were observed between the groups. Ab, antibody; JAM-C, junctional adhesion molecule-C